NovaBridge Biosciences (NBP) Cash & Equivalents (2018 - 2025)

NovaBridge Biosciences (NBP) has reported Cash & Equivalents for 8 consecutive years, with $210.6 million the latest figure, recorded in Q4 2025.

• Quarterly Cash & Equivalents rose 208.56% year-over-year to $210.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $210.6 million (up 208.56% YoY) and the FY2025 annual result came in at $210.6 million, up 208.56% from the prior year.
• Cash & Equivalents slipped to $210.6 million in Q4 2025 per NBP's latest filing, from $228.1 million in the prior quarter.
• Over the last five years, Cash & Equivalents for NBP reached as high as $672.5 million in Q2 2021 and fell as low as $53.6 million in Q1 2025.
• A 5-year average of $293.0 million and a median of $228.1 million in 2025 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2024 — Cash & Equivalents plunged 77.05% — and 2025, when it jumped 208.56%.
• Year by year, Cash & Equivalents stood at $551.1 million in 2021, then slipped by 18.0% to $451.9 million in 2022, then sank by 34.18% to $297.4 million in 2023, then tumbled by 77.05% to $68.3 million in 2024, then soared by 208.56% to $210.6 million in 2025.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $210.6 million, $228.1 million, and $165.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.